Drug Profile
Enhanced umbilical cord adherent stem cell - CHA Biotech
Alternative Names: CordSTEM-ARDS; CordSTEM-AS; CordSTEM-CD; CordSTEM-COVID; CordSTEM-DD; Cordstem-ST; CordSTEM®; Human umbilical cord derived mesenchymal stem cell therapy - CHA BiotechLatest Information Update: 07 Sep 2023
Price :
$50
*
At a glance
- Originator CHA Bio & Diostech
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Intervertebral disc degeneration; Stroke
- Preclinical Cartilage disorders; Female genital diseases; SARS-CoV-2 acute respiratory disease
Most Recent Events
- 17 Apr 2023 CHABiotech completes a Phase-I/II clinical trials in Intervertebral disc degeneration in South Korea (Parenteral) (NCT04530071)
- 18 Mar 2021 Phase-I clinical trials in Intervertebral disc degeneration in South Korea (Parenteral) before March 2021 (CHA Biotech pipeline, March 2021)
- 18 Mar 2021 Preclinical trials in Female genital diseases in South Korea (Parenteral) before March 2021 (CHA Biotech pipeline, March 2021)